Zydus Cadila completes patient enrollment in 3 phase III trials of Saroglitazar Magnesium for NASH

Zydus Cadila Thursday said it has completed enrollment of patients in three phase III trials of Saroglitazar Magnesium for Non-Alcoholic SteatoHepatitis (NASH), a progressive disease of the liver. "Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico," Cadila Healthcare, the listed entity of the group, said in a BSE filing.

"We are excited about the progress that Saroglitazar Mg has been making in the NASH trials. It is currently being evaluated in over 23 different controlled clinical trials, involving over 3,800 patients," Zydus Group Chairman Pankaj R Patel said in BSE filing. "NASH is an area of unmet healthcare need and we are committed to develop this therapy for millions of patients suffering from this deadly disease," he added.

Shares of Cadila Healthcare were trading 0.85 per cent lower at Rs 238.55 apiece on BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)